Since the first associations between de novo cancer and immunosuppression in renal allograft recipients were reported by Doak [1], Starzl [2] and Zukoski [3] in 1968, it has become increasingly clear that organ transplant patients are at increased risk for development of malignancy. However, the pattern of cancer incidence in transplant recipients is distinctly different from that in the general population, with a marked excess in the occurrence of carcinoma of the skin and lips, non-Hodgkin's lymphoma (NHL)...

Keywords: transplant, cancer, PTLD